设为首页 加入收藏

TOP

Afatinib(阿法替尼片,GILOTRIF,Giotrif)(十二)
2013-09-17 16:35:11 来源: 作者: 【 】 浏览:10079次 评论:0
98;    Median Progression-free Survival (months) 11.1 6.9
          95% CI (9.6, 13.6) (5.4, 8.2)
          HR (95% CI) 0.58 (0.43, 0.78)
          Stratified Log-Rank Test P-value* <0.001
Overall Survival
Number of Deaths, N (%) 116 (50.4%) 59 (51.2%)
          Median Overall Survival (months) 28.1 28.2
          95% CI (24.6, 33.0) (20.7, 33.2)
          HR (95% CI) 0.91 (0.66, 1.25)
          Stratified Log-Rank Test P-value* 0.55
Objective Response Rate (CR + PR)
          N (%) 116 (50.4%) 22 (19.1%)
Response Duration
Median (months) 12.5 6.7
Subgroup analyses were conducted based on the stratification factor of EGFR mutation status (Del19, L858R, other) and mutation category (common [Del19, L858R] vs uncommon [other]). See Figure 2.

There were 26 GILOTRIF-treated patients in the “other” (uncommon) EGFR mutations subgroup with nine unique mutation patterns. None of these 26 patients achieved a complete response, while four achieved a partial response (see Table 4 below). No responses were seen in GILOTRIF-treated patients with the following mutations: T790M alone (n=2), deletion 19 and T790M (n=3), G719X and T790M (n=1), exon 20 insertion (n=6), and L861Q alone (n=3). There were 11 chemotherapy-treated patients in the “other” uncommon EGFR mutation subgroup; of these, four (36%) achieved a partial response.
Table 4 Objective Tumor Responses in GILOTRIF-Treated Patients Based on Investigator Assessment in the “Other” (Uncommon) EGFR Mutation Subgroup + Censored observation
EGFR Mutations Number of GILOTRIF-Treated Patients Number of Patients with Partial Responses Duration of Response
        L858R and T790M 5 1    6.9 months
        L858R and S768I 2 1 12.4+ months
        S768I 1 1 16.5+ months
        G719X 3 1    9.6 months
16  HOW SUPPLIED/STORAGE AND HANDLING
GILOTRIF tablets are available as follows:
40 mg: light blue, film-coated, round, biconvex, bevel-edged tablets debossed with “T40” on one side and the Boehringer Ingelheim company symbol on the other side.
Unit of use bottles of 30                 NDC: 0597-0138-30

30 mg: dark blue, film-coated, round, biconvex, bevel-edged tablets debossed with “T30” on one side and the Boehringer Ingelheim company symbol on the other side.
Unit of use bottles of 30            ̳

以下是“全球医药”详细资料
Tags: 责任编辑:admin
首页 上一页 9 10 11 12 13 14 15 下一页 尾页 12/17/17
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Edarbi (azilsartan medoxomil) t.. 下一篇OSENI (alogliptin and pioglitaz..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位